During the past decade, Instituto Nacional de Enfermedades Neoplasicas conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 28 clinical trials were completed, i.e. on average, 121.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 8 clinical trials were completed. i.e. 88.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Nacional de Enfermedades Neoplasicas" #1 sponsor was "Hoffmann-La Roche" with 20 trials, followed by "National Cancer Institute (NCI)" with 10 trials sponsored, "ETOP IBCSG Partners Foundation" with 6 trials sponsored, "Eastern Cooperative Oncology Group" with 5 trials sponsored and "Alliance for Clinical Trials in Oncology" with 5 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Nacional de Enfermedades Neoplasicas" #1 collaborator was "National Cancer Institute (NCI)" with 21 trials as a collaborator, "Eastern Cooperative Oncology Group" with 7 trials as a collaborator, "Cancer and Leukemia Group B" with 6 trials as a collaborator, "Breast International Group" with 5 trials as a collaborator and "SWOG Cancer Research Network" with 5 trials as a collaborator. Other collaborators include 50 different institutions and companies that were collaborators in the rest 52 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Nacional de Enfermedades Neoplasicas" are "Breast Cancer" (18 trials), "Breast Adenocarcinoma" (3 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials), "Breast Neoplasms" (2 trials) and "Gastric Cancer" (2 trials). Many other conditions were trialed in "Instituto Nacional de Enfermedades Neoplasicas" in a lesser frequency.

Most popular intervention types in "Instituto Nacional de Enfermedades Neoplasicas" are "Drug" (55 trials), "Other" (12 trials), "Biological" (11 trials), "Procedure" (10 trials) and "Radiation" (8 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (12 trials), "Atezolizumab" (10 trials), "Bevacizumab" (10 trials), "Cyclophosphamide" (7 trials) and "Carboplatin" (6 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Nacional de Enfermedades Neoplasicas" are 52 trials for "All" genders, 18 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Nacional de Enfermedades Neoplasicas". undefined are not yet recruiting, 6 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 38 completed trials in Instituto Nacional de Enfermedades Neoplasicas, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Nacional de Enfermedades Neoplasicas, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 47 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".